pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Sep 12·1 min read
save

Novartis encounters setbacks while AI firm Anthropic searches for a dealmaker

Sep 12, 2026·read at Endpoints ↗Neutral

The latest Endpoints Weekly edition highlights a difficult period for Novartis, noting that the company is facing a series of setbacks.

Details of the challenges are not provided, but the report signals a negative trend for the Swiss drugmaker.

In a separate note, Anthropic, an artificial‑intelligence company, is actively looking for a dealmaker to advance its strategic objectives.

The newsletter frames both items as part of a broader industry update for readers interested in pharma and biotech developments.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “Setbacks for Novartis; Anthropic looks for a dealmaker; and more”

read at Endpoints ↗
85 words · retrieved Sep 12
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
NOVARTIS2

related stories

  • Jun 11STAT+: Enliven Therapeutics’ leukemia drug shows promise in new studySTAT
  • Jun 10Novartis and Orionis strike second molecular glue deal for $40M upfrontEndpoints
  • Jun 8Incyte to buy blood disorder drug in possibly $2B dealBioPharma Dive
  • Jun 3Legend surges on early data for ‘in vivo’ lymphoma cell therapyBioPharma Dive
  • Jun 2Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trialBioPharma Dive